

References

- Gillmore JD et al., Gane E, Taubel J, et al. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. *N Engl J Med.* 2021;385(6):493-502.
- Li F, Ng WL, Luster TA, et al. Epigenetic CRISPR Screens Identify *Npm1* as a Therapeutic Vulnerability in Non-Small Cell Lung Cancer. *Cancer Res.* 2020;80(17):3556-3567
- Huang K, Yang C, Wang QX, et al. The CRISPR/Cas9 system targeting EGFR exon 17 abrogates NF- κ B activation via epigenetic modulation of UBXN1 in EGFRwt/vIII glioma cells. *Cancer Lett.* 2017;388:269-280.
- Rattanasinchai C, Llewellyn BJ, Conrad SE, Gallo KA. MLK3 regulates FRA-1 and MMPs to drive invasion and transendothelial migration in triple-negative breast cancer cells. *Oncogenesis.* 2017;6(6):e345. Published 2017 Jun 12
- Zhang S, Fan G, Hao Y, Hammell M, Wilkinson JE, Tonks NK. Suppression of protein tyrosine phosphatase N23 predisposes to breast tumorigenesis via activation of FYN kinase. *Genes Dev.* 2017;31(19):1939-1957

